Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8).
Diabetes Obes MetabJul 1, 2026 (epub)
Krzysztof Strojek, Andreas Liebl, Neha Narendra Mumbaikar et al.
✦ AI-curated · Sources linked
In 30 seconds
The ONWARDS 8 trial evaluated the efficacy and safety of intensifying once-weekly insulin icodec with semaglutide in adults with type 2 diabetes. This single-arm, open-label, Phase 3b trial involved 148 participants, with 94 receiving semaglutide. The mean HbA1c decreased from 7.88% to 6.66% over 52 weeks, demonstrating a significant reduction of -1.23%-points (p < 0.0001).
Key findings
- Mean HbA1c decreased from 7.88% to 6.66% over 52 weeks.
- Estimated mean change in HbA1c was -1.23%-points (95% CI: -1.39, -1.07%-points).
- Body weight decreased by an average of -3.85 kg (p < 0.0001).
- Rate of clinically significant or severe hypoglycaemia was 0.24 episodes per person-year.
Why it matters
This study highlights a potential treatment strategy for adults with type 2 diabetes, showing that combining insulin icodec with semaglutide can effectively lower HbA1c levels while maintaining a low risk of hypoglycaemia.